ABC | Volume 115, Nº2, Agosto 2020

Artigo Original Mattos BP et al. Morte súbita na cardiomiopatia hipertrófica Arq Bras Cardiol. 2020; 115(2):197-204 5. O’Mahony C, Elliott PM. Prevention of sudden cardiac death in hypertrophic cardiomyopathy. Heart. 2014;100(3):254-60. 6. Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Heart Rhythm. 2016;13(5):1155-65. 7. Weissler-Snir A, Adler A, Williams L, Gruner C, Rakowski H. Prevention of sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowledge. Eur Heart J. 2017;38(22):1728-37. 8. Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36(7):2212-8. 9. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24):1778-85. 10. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-LadoM, McKennaWJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J Am Coll Cardiol. 2003;42(5):873-9. 11. Elliott PM, Gimeno JR, Tomé MT , Shah J, Ward D, Thaman R, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27(16):1933-41. 12. Spirito P, Autore C, Rapezzi C, Bernabò P, Badagliacca R, Maron MS, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009;119(13):1703-10. 13. Christiaans I, van Engelen K, van Langen IM, Birnie E, Bonsel GJ, Elliott PM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace. 2010;12(3):313-21. 14. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et. al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation task force on clinical expert consensus documents and the European Society of Cardiology Committee for practice guidelines. J Am Coll Cardiol. 2003;42(9):1687-713. 15. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/AmericanHeart Association Task ForceOn Practice Guidelines. Circulation. 2011;124(24):2761-96. 16. O’Mahony C, Jichi F , Pavlou M, Monserrat L4, Anastasakis A5, Rapezzi C, et al.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010-20. 17. Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-79. 18. Mattos BP, Scolari FL, Torres MAR, Simon L, Freitas VC, Giugliani R, et al. Prevalence and phenotypic expression of mutations in the MYH7, MYBPC3 and TNNT2 genes in families with hypertrophic cardiomyopathy in the south of Brazil: a cross-sectional study. Arq Bras Cardiol. 2016;107(3):257-65. 19. Shiozaki AA, Senra T, Arteaga E, Pita CG, Martinelli Filho M, Ávila LFR, et al. Myocardial fibrosis in patients with hypertrophic cardiomyopathy and high risk for sudden death. Arq Bras Cardiol. 2010;94(4):535-40. 20. Mattos BP, Torres MAR, Freitas VC, Scolari FL, Loreto MS. Ventricular arrhythmias and left ventricular hypertrophy in hypertrophic cardiomyopathy. Arq Bras Cardiol. 2013;100(5):452-9. 21. Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014;113(9):1550-5. 22. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et. al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298(4):405-12. 23. O’Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, et al. A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. Heart. 2013;99(8):534-41. 24. Vriesendorp PA, Schinkel AF , Liebregts M, Theuns DA, van Cleemput J, Ten Cate FJ, et al. Validation of the 2014 European Society of Cardiology guidelinesriskpredictionmodelfortheprimarypreventionofsuddencardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(4):829-35. 25. Ruiz-Salas A, García-Pinilla JM, Cabrera-Bueno F , Fernández-Pastor J, Peña-Hernández J, Medina-Palomo C, et al. Comparison of the new risk predictionmodel (HCMRisk-SCD) and classic risk factors for sudden death in patients with hypertrophic cardiomyopathy and defibrillator. Europace. 2016;18(5):773-7. 26. Fernández A, Quiroga A, Ochoa JP, Mysuta M, Casabé JH, Biagetti M, et al. Validation of the 2014 European Society of Cardiology sudden cardiac death risk predictionmodel in hypertrophic cardiomyopathy in a reference center in South America. Am J Cardiol. 2016;118(1):121-6. 27. O’Mahony C, Jichi F , Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al.. International external validation study of the 2014 European Society of Cardiology guidelines on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-HCM). Circulation. 2018;137(10):1015-23. 28. Nakagawa S, Okada A, Nishimura K, Hamatani Y, Amano M, Takahama H, et al. Validation of the 2014 European Society of Cardiology sudden cardiac death risk predictionmodel among various phenotypes in Japanese patients with hypertrophic cardiomyopathy. Am J Cardiol. 2018;122(11):1939-46. 29. Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116(5):757-64. 30. Leong KMW, Chow JJ, Ng FS, Falaschetti E, Qureshi N, Koa-Wing M, et al. Comparison of the prognostic usefulness of the European Society of Cardiology andAmericanHeart Association/AmericanCollege of Cardiology Foundation risk stratification systems for patients with hypertrophic cardiomyopathy. Am J Cardiol. 2018;121(3):349-55. 31. Desai MY, Smedira NG, Dhillon A, Masri A, Wazni O, Kanj M, et al. Predictionofsuddendeathrisk inobstructivehypertrophiccardiomyopathy: potential for refinement of current criteria. J Thorac Cardiovasc Surg. 2018;156(2):750-9. 32. Reis L, Teixeira R, Fernandes A, Almeida I, Madeira M, Silva J, et al. Prevention of sudden cardiac death in hypertrophic cardiomyopathy: what has changed in the guidelines? Arq Bras Cardiol. 2018;110(6):524-31. 33. O’Mahony C, Akhtar MM, Anastasiou Z, Guttmann OP, Vriesendorp PA, Michels M, et al. Effectiveness of the 2014 European Society of Cardiology guideline on sudden cardiac death in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart. 2019;105(8):623-31. Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 204